← Back to Search

PET/MRI Imaging for Endometrial Cancer

N/A
Waitlist Available
Led By Onofrio Catalono, MD, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women aged 18-85 years old with an endometrial biopsy-confirmed diagnosis of either grade 3 endometrioid, serous, carcinosarcoma, undifferentiated or mixed cell carcinoma
Planning to undergo cytoreductive surgery with a Gynecologic oncologist employed by Massachusetts General Hospital
Must not have
Is unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis)
A history of chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is investigating whether PET/MRI is more effective than the currently used imaging modalities (CT, or PET/CT) for high-risk endometrial cancer.

Who is the study for?
This trial is for women aged 18-85 with certain high-risk endometrial cancers, presumed to be in early stage, and planning surgery at Massachusetts General Hospital. They must have proper kidney function. It excludes those over 300lbs or BMI >33, with specific implants, claustrophobia, excessive prior radiation exposure, severe renal issues or under the investigator's care.
What is being tested?
The study tests if PET/MRI scans using a radiotracer and contrast agent are better than current CT or PET/CT imaging for detecting high-risk endometrial cancer before surgery.
What are the potential side effects?
Possible side effects include reactions to the radiotracer or contrast agent like nausea or rash; discomfort from lying still during scanning; anxiety due to confinement in the scanner space (claustrophobia).

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 18-85 with a specific type of uterine cancer confirmed by biopsy.
Select...
I plan to have surgery to reduce tumor size with a specialist at Massachusetts General Hospital.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot lie comfortably on my back due to pain or arthritis.
Select...
I have severe chronic kidney problems.
Select...
I am between 18 and 85 years old.
Select...
My weight is over 300lbs or my BMI is above 33.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of patients with a metastatic lesion noted on PET/MRI that have a true malignancy noted on surgical pathology of that lesion
Percentage of patients without any metastatic lesion noted on PET/MRI that do not have malignancy noted on surgical pathology

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET/MRI IN ENDOMETRIAL CANCERExperimental Treatment1 Intervention
PET/MRI in one study visit of approximately four hours

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,006 Previous Clinical Trials
13,307,282 Total Patients Enrolled
Onofrio Catalono, MD, PhDPrincipal InvestigatorMassachusetts General Hospital

Media Library

PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent Clinical Trial Eligibility Overview. Trial Name: NCT05390021 — N/A
Cytoreductive Surgery Research Study Groups: PET/MRI IN ENDOMETRIAL CANCER
Cytoreductive Surgery Clinical Trial 2023: PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent Highlights & Side Effects. Trial Name: NCT05390021 — N/A
PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent 2023 Treatment Timeline for Medical Study. Trial Name: NCT05390021 — N/A
~0 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top